NASDAQ · Health care

Scienture Holdings, Inc. (SCNX)

It posted a net loss of $38M. At June 30, 2026 it held $8.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$0.28

-3.35% on the day · September 25, 2026

52-week range $0.24 to $2.60

Market cap

$11.4M

What Scienture Holdings, Inc. does

Scienture Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SCNX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$431.6K	-$42.6M	-$41.5M	-$2.70	n/a
2024	$136.6K	-$14.7M	$9.1M	$2.48	-$14.3M
2023	$1.4M	-$4.4M	-$17.8M	-$23.35	n/a
2022	$10.3M	-$2.9M	-$3.5M	-$19.11	n/a
2021	$9.9M	-$5.3M	-$5.3M	-$30.30	-$2.6M
2020	$17.1M	-$2.5M	-$2.5M	-$15.38	-$2.3M

Where SCNX ranks in Health care

Revenue$431.6K

#597 of 646 in Health care · Bottom 8%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out $14.9M in cash dividends, 164% of its net income.

Fiscal year	Per share	Paid out	Of profit
2024	n/a	$14.9M	164%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Scienture Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 18, 2026
Proxy statement DEF 14A
September 14, 2026
Investor disclosure 8-K
September 8, 2026
Preliminary proxy statement PRE 14A
August 20, 2026
Quarterly results 8-K
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue was $343.6K; diluted EPS -$0.07 versus -$0.48.
May 29, 2026
Executive or director change 8-K
May 22, 2026
Quarterly results 8-K
May 15, 2026
Quarterly report 10-Q · period to March 31, 2026Revenue rose 449% to $56.3K versus the same quarter last year; diluted EPS -$0.08 versus -$0.33.
May 5, 2026
Investor disclosure 8-K
May 1, 2026
Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 31, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about SCNX

What does Scienture Holdings, Inc. do?

Scienture Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SCNX.

Is Scienture Holdings, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $38M.

When did Scienture Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 18, 2026.

Similar companies

Compare SCNX with

Compare SCNX with any company

Follow SCNX

Get an email when Scienture Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SCNX: get an email when it files

Where the numbers come from

Financial figures are the values Scienture Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.